These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8908943)

  • 21. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

  • 22. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
    van de Werf F
    Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycoprotein IIb/IIIa inhibitors: more different than alike?
    Stone GW
    Catheter Cardiovasc Interv; 2001 Jul; 53(3):304-7. PubMed ID: 11458404
    [No Abstract]   [Full Text] [Related]  

  • 26. Minimally invasive bypass surgery.
    Dragu RE
    N Engl J Med; 2002 Dec; 347(26):2165-8; author reply 2165-8. PubMed ID: 12501850
    [No Abstract]   [Full Text] [Related]  

  • 27. Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
    Roe MT; Moliterno DJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):247-57. PubMed ID: 10373718
    [No Abstract]   [Full Text] [Related]  

  • 28. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
    van Hout BA; Bowman L; Zelinger DJ; Simoons ML
    Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The TARGET trial: hit or miss?
    Moliterno DJ; Topol EJ
    Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Parmar R; Stouffer GA
    Am J Med Sci; 1997 Jul; 314(1):31-6. PubMed ID: 9216438
    [No Abstract]   [Full Text] [Related]  

  • 31. In the era of stabilize and seal, is there a role for GP IIb/IIIa agents in PCI?
    Gilchrist IC
    Catheter Cardiovasc Interv; 2010 May; 75(6):903-4. PubMed ID: 20432396
    [No Abstract]   [Full Text] [Related]  

  • 32. Improving microvascular perfusion with platelet glycoprotein IIb/IIIa receptor inhibition.
    Dippel EJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():12E-16E; quiz 17E. PubMed ID: 12668858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal treatment of acute coronary syndromes--an evolving strategy.
    Boden WE; McKay RG
    N Engl J Med; 2001 Jun; 344(25):1939-42. PubMed ID: 11419433
    [No Abstract]   [Full Text] [Related]  

  • 35. Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents.
    Gershlick AH
    Semin Interv Cardiol; 1998; 3(3-4):185-90. PubMed ID: 10406691
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimization of platelet therapy.
    Fry JA; Grines CL
    Semin Interv Cardiol; 2000 Sep; 5(3):117-28. PubMed ID: 11054909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
    Saw J; Moliterno DJ
    Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902
    [No Abstract]   [Full Text] [Related]  

  • 38. Interventional therapy for coronary artery disease.
    Shah PB; Lilly CM
    Am J Respir Crit Care Med; 2002 Sep; 166(6):791-6. PubMed ID: 12231486
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Rescue platelet glycoprotein IIb/IIIa inhibitor therapy in thrombosis complicating superficial femoral artery angioplasty.
    Grollman JH; Coil A
    Cardiovasc Intervent Radiol; 2002; 25(1):77-80. PubMed ID: 11907783
    [No Abstract]   [Full Text] [Related]  

  • 40. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off?
    Jeremias A; Gruberg L
    J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.